Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) and CDT Equity (NASDAQ:CDT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings.
Volatility and Risk
Xenetic Biosciences has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500. Comparatively, CDT Equity has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500.
Valuation & Earnings
This table compares Xenetic Biosciences and CDT Equity”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xenetic Biosciences | $2.98 million | 1.94 | -$2.68 million | ($1.20) | -2.10 |
| CDT Equity | N/A | N/A | -$39.22 million | ($14,265.60) | -0.00 |
Xenetic Biosciences has higher revenue and earnings than CDT Equity. Xenetic Biosciences is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Xenetic Biosciences and CDT Equity’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xenetic Biosciences | -70.03% | -39.28% | -33.47% |
| CDT Equity | N/A | -145.29% | -103.25% |
Insider & Institutional Ownership
15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 7.6% of Xenetic Biosciences shares are held by insiders. Comparatively, 10.8% of CDT Equity shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Xenetic Biosciences and CDT Equity, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xenetic Biosciences | 1 | 0 | 0 | 0 | 1.00 |
| CDT Equity | 1 | 0 | 0 | 0 | 1.00 |
Summary
Xenetic Biosciences beats CDT Equity on 7 of the 10 factors compared between the two stocks.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
About CDT Equity
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
